Leonard L, Lippe M, Follansbee S, Drennan D, Karol C; International Conference on AIDS.
Int Conf AIDS. 1990 Jun 20-23; 6: 231 (abstract no. Th.B.436).
Davies Medical Center, San Francisco, CA, USA
OBJECTIVE: To evaluate the safety and efficacy of foscarnet treatment of CMV retinitis in AIDS patients. METHODS: Patients with AIDS and active CMV retinitis were enrolled. Some, but not all patients had prior DHPG treatment. Those completing a 14-21 day induction phase of intermittent intravenous infusions were randomized to an every 12 or every 24 hour maintenance dose regimen. Measures of central tendency and percentages are used for preliminary description of the findings. RESULTS: Thirty-six patients were enrolled. Nineteen (55.8%) were randomized to maintenance; 7 (36.8%) patients experienced a relapse of retinitis (mean time 40 days on maintenance). Four patients (21%) completed the prescribed study course. Sixteen of 26 patients (61.5%) experienced a decrease in disease activity within the first 21 days of therapy. Eighteen patients (50%) developed serious toxicities and were removed from the study; 44% of these were due to renal impairment. Other drug limiting toxicities included 3 episodes of penile fixed drug eruptions. CONCLUSION: Foscarnet is an effective treatment for CMV retinitis. Although 50% of patients studied developed serious toxicities, these can be controlled in most patients through careful monitoring and appropriate dose modifications. The proper dose for maintenance remains to be determined.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Clinical Protocols
- Cytomegalovirus Retinitis
- Drug Therapy, Combination
- Foscarnet
- Humans
- Retinitis
- drug therapy
- therapy
Other ID:
UI: 102182012
From Meeting Abstracts